Cytomegalovirus and Human Herpes Virus-6 Reactivation Following Tandem Transplantation Autologous Peripheral Blood Stem Cell Transplantation for Multiple Myeloma (MM)

Abstract

s / Biol Blood Marrow Transplant 22 (2016) S19eS481 S178 CMV serostatus was positive in 51 patients. Overall 23 (24.2% overall, 45.1% in seropositive patients) patients had CMV reactivation of which 11 had reactivation after first transplant, 8 after second and 4 after both transplants. 13 patients received treatment with foscarnet, valganciclovir and/or ganciclovir. CMV symptoms were fever (4 patients), pneumonitis (2) and possible pericarditis (1) and esophagitis (1). No CMV reactivation was seen in seronegative patients. Seven patients were found to have HHV-6 reactivation, 4 after first and 3 after second transplant. Two patients needed treatment with foscarnet and ganciclovir. HHV-6 symptoms were fever (1 patient) and possible encephalitis (1). With early treatment, no death occurred due to CMV and HHV-6 reactivation. Conclusions: Our experience shows that CMV reactivation is very common (almost 50%) in CMV seropositive patients whereas HHV-6 reactivation is relatively rare. CMV surveillance should be performed routinely after APBSCT.